What is Olprezide used for?

Olprezide

Active Ingredient:: Olmesartan Medoxomil, Hydrochlorothiazide
Origin:: EU

Olprezide (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxomil, the active ingredient in Olprezide, is an angiotensin II receptor blocker (ARB) presented as a oral tablet for systemic use. It treats hypertension, often in combination with a diuretic, and is intended for adult patients. GNH India supplies Olprezide as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH India supplies Olprezide as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Menarini International Operations Luxembourg S.A.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Olprezide is an antihypertensive medication that acts on the renin‑angiotensin system to lower blood pressure.

Hypertension: helps lower systolic and diastolic blood pressure in adults.
Heart failure: used as part of combination therapy to improve fluid balance and reduce cardiac workload.
Diabetic nephropathy: contributes to renal protection by controlling blood pressure in patients with type 2 diabetes.

How It Works

Olprezide combines olmesartan medoxomil, an angiotensin II type 1 (AT1) receptor antagonist, with hydrochlorothiazide, a thiazide‑type diuretic that inhibits sodium‑chloride reabsorption in the distal convoluted tubule. Blocking AT1 receptors prevents vasoconstriction and aldosterone release, while the diuretic promotes natriuresis and reduces plasma volume, together producing a sustained reduction in systemic vascular resistance and blood pressure.

Side Effects

Olprezide may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

Dizziness or light‑headedness
Headache
Fatigue
Increased urination
Electrolyte disturbances (e.g., low potassium)
Mild gastrointestinal discomfort

Serious or Rare Side Effects

Severe hypotension
Acute kidney injury
Hyperkalemia
Angio‑edema
Severe electrolyte imbalance
Hepatic dysfunction

Precautions & Warnings

Before starting Olprezide, patients should be evaluated for several safety considerations.

Renal function: assess baseline kidney function and monitor periodically.
Electrolytes: check serum potassium and sodium levels before initiation and during therapy.
Pregnancy: avoid use during pregnancy, especially the second and third trimesters.
Concomitant drugs: review other antihypertensives or potassium‑sparing agents.
Elderly patients: start at lower doses and monitor for orthostatic symptoms.
Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Olprezide can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

Aliskiren: combined use with an ARB may increase risk of renal impairment and hyperkalemia.
Lithium: concurrent use can raise lithium levels, risking toxicity.
Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalemia.

Moderate Interactions (Monitor Closely)

Non‑steroidal anti‑inflammatory drugs (NSAIDs): may reduce antihypertensive effect and impair renal function.
ACE inhibitors: combined use can increase risk of hypotension and kidney injury.
Antidiabetic drugs: may require dose adjustment due to enhanced glucose‑lowering effect.

Frequently Asked Questions

Olprezide is a fixed‑dose combination of olmesartan medoxill and hydrochlorothiazide that is prescribed to lower high blood pressure and to help manage fluid retention in conditions such as hypertension and certain forms of heart failure. It works as part of a broader antihypertensive regimen and is typically used when monotherapy does not achieve target blood pressure levels.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 04 Oct 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.